Oppenheimer Asset Management Inc. Buys 8,779 Shares of Bristol Myers Squibb Company $BMY

Posted by Stanley Muller on Aug 15th, 2026

Oppenheimer Asset Management Inc. grew its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 1.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 495,604 shares of the biopharmaceutical company’s stock after buying an additional 8,779 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Bristol Myers Squibb were worth $28,557,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in BMY. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $25,000. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the second quarter worth $25,000. Physician Wealth Advisors Inc. increased its stake in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the last quarter. Bayban purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the fourth quarter worth about $32,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 1.2%

BMY opened at $63.86 on Friday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.10. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The business’s 50-day moving average price is $59.56 and its 200-day moving average price is $58.97. The company has a market cap of $130.45 billion, a P/E ratio of 14.07, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. During the same period in the prior year, the business posted $1.46 EPS. Bristol Myers Squibb’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.96 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.9%. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Roth Capital initiated coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective on the stock. UBS Group downgraded Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Jefferies Financial Group lowered Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a research report on Friday, July 31st. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Get Our Latest Analysis on BMY

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.